ARTCLINE
ARTCLINE GmbH develops a novel immune cell-based extracorporeal sepsis therapy. Their ARTICE® therapy uses immune cells from healthy donors to assist and reactivate the patient's immune system in cases of septic shock. This aims to address the significant challenge of sepsis in healthcare systems worldwide.
Funding Round:
Funding Amount: €4.4M
Date: 25-Mar-2024
Investors: family offices from Germany
Markets: Healthtech, Biotechnology Research, Medical
HQ: Rostock, Mecklenburg-Vorpommern, Germany
Founded: 2007
Website: https://www.artcline.de/
LinkedIn: https://www.linkedin.com/company/artcline
Twitter: https://twitter.com/ARTCLINE_
Crunchbase: https://www.crunchbase.com/organization/artcline
Leave a Comment
Comments
No comments yet.